Table 1

Distribution of genotype polymorphisms of estrogen-metabolizing genes, CYP17, CYP1A1, and COMT, and estimated OR and aOR in relation to breast cancer risk

Genotype of estrogen-metabolizing geneNo. of cases (%)No. of controls (%)OR (95% CI)aOR (95% CI)a
Total women
CYP17
  A1/A125 (20.3)28 (22.2)1.00 (Ref)b    ]1.00 (Ref)
  A1/A254 (43.9)63 (50.0)0.96 (0.48–1.94)
  A2/A244 (35.8)35 (27.8)1.41 (0.66–3.01)1.28 (0.73–2.27)
CYP1A1 MspI
  wt/wt48 (35.3)45 (33.8)1.00 (Ref)     ]1.00 (Ref)
  wt/vt56 (41.2)71 (53.4)0.74 (0.42–1.31)
  vt/vt32 (23.5)17 (12.8)1.76 (0.81–3.85)2.11 (1.08–4.20)
COMT
  H/H68 (57.6)66 (52.8)1.00 (Ref)     ]1.00 (Ref)
  H/L37 (31.4)55 (44.0)0.65 (0.37–1.16)
  L/L13 (11.0)4 (3.2)3.15 (0.89–12.15)3.55 (1.15–13.37)
Premenopausal women
CYP17
  A1/A110 (19.2)12 (24.0)1.00 (Ref)     ]1.00 (Ref)
  A1/A225 (48.1)24 (48.0)1.25 (0.41–3.87)
  A2/A217 (32.7)14 (28.0)1.46 (0.42–5.06)1.18 (0.50–2.83)
CYP1A1 MspI
  wt/wt24 (42.9)18 (32.7)1.00 (Ref)     ]1.00 (Ref)
  wt/vt21 (37.5)29 (52.7)0.54 (0.22–1.35)
  vt/vt11 (19.6)8 (12.6)1.03 (0.30–3.55)1.79 (0.64–5.24)
COMT
  H/H29 (60.4)31 (59.6)1.00 (Ref)     ]1.00 (Ref)
  H/L14 (29.2)18 (34.6)0.83 (0.32–2.15)
  L/L5 (10.4)3 (5.8)1.78 (0.33–10.51)2.00 (0.46–10.36)
Postmenopausal women
CYP17
  A1/A114 (20.6)15 (20.0)1.00 (Ref)     ]1.00 (Ref)
  A1/A227 (39.7)39 (52.0)0.74 (0.28–1.95)
  A2/A227 (39.7)21 (28.0)1.38 (0.49–3.85)1.31 (0.59–2.90)
CYP1A1
  wt/wt
  wt/wt21 (28.0)27 (35.1)1.00 (Ref)     ]1.00 (Ref)
  wt/vt33 (44.0)41 (53.2)1.03 (0.47–2.30)
  vt/vt21 (28.0)9 (11.7)3.00 (1.03–8.89)2.15 (0.84–5.72)
COMT
  H/H37 (56.9)34 (47.2)1.00 (Ref)     ]1.00 (Ref)
  H/L21 (32.3)37 (51.4)0.52 (0.24–1.13)
  L/L7 (10.8)1 (1.4)6.43 (0.72–146)9.34 (1.27–193)
  • a ORs and 95% CIs were calculated by logistic regression models containing breast cancer risk factors. Risk factors were adjusted for age, family history of breast cancer, age at menarche, age at FFTP, and history of HRT in the groups of total women and postmenopausal women. For premenopausal women, the history of HRT was not included in the model.

  • b Ref, reference group.